Melanoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Melanoma Emerging Therapy and TPP Insights

Thelansis’s “Melanoma Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Melanoma Overview

Melanoma is an aggressive malignancy arising from melanocytes — pigment-producing cells residing predominantly in the skin but also in ocular and mucosal sites — representing the most lethal form of skin cancer due to its pronounced metastatic potential. Ultraviolet radiation-induced DNA damage, particularly cyclobutane pyrimidine dimer formation, drives mutagenesis in sporadic melanoma, while germline CDKN2A mutations underlie familial predisposition. Somatic driver mutations — BRAF V600 in approximately 50%, NRAS in 15-20%, and NF1 or KIT alterations in the remaining subtypes — activate MAPK and PI3K survival pathways. Patients present with evolving pigmented lesions characterised by the ABCDE criteria — asymmetry, border irregularity, colour variation, diameter, and evolution — with diagnosis established by excisional biopsy and histopathological assessment, including Breslow thickness, ulceration, and mitotic rate. Sentinel lymph node biopsy guides locoregional staging, while PET-CT and brain MRI are essential for metastatic evaluation. Surgical excision with appropriate margins remains the cornerstone for localised disease. Adjuvant therapy — pembrolizumab, nivolumab, or BRAF-MEK inhibitor combinations in BRAF-mutated disease — reduces recurrence risk in high-risk resected melanoma. Advanced disease management mirrors metastatic cutaneous melanoma — immune checkpoint inhibitors, BRAF-MEK targeted combinations, and lifileucel TIL therapy for refractory disease. Prognosis is stage-dependent; multidisciplinary management, dermoscopic surveillance, sun protection education, and patient-centred care are integral to optimising outcomes.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Read more: Melanoma – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026